Dr. Reddy’s introduces generic Gleevec tablets
Dr. Reddy’s is launching imatinib mesylate tablets, a generic version of Novartis Pharmaceuticals’ Gleevec (imatinib mesylate) tablets.
The medication is used to treat chronic myelogenous leukemia, or CML, and acute lymphocytic leukemia, or ALL, that are Philadelphia chromosome-positive, or Ph+, and certain types of gastrointestinal stromal tumors, or GIST, systemic mastocytosis and myelodysplastic syndrome.
Dr. Reddy’s imatinib mesylate tablets are available in 100 mg 30-count and 400 mg 90-count bottle sizes.
The Gleevec brand and generic had a market value of approximately $868 million for the most recent 12 months ending in July 2018, according to IQVIA.
No comments found